Pharmaceutical companies face testing times. Stakeholder expectations are changing and development pipelines look bleak, compounded by impending patent expiries and pressures from the generics market. Their future is moving away from blockbuster drug discovery to diversified portfolios, collaboration with academia and the development of biotechnology driven discovery, supported by government agendas worldwide.

To survive and grow these companies need flexible strategies and innovative business models. Their asset strategies must also support revenue generation and the drive to lower costs.

Working on £1bn worth of pharmaceutical related capital programmes a year, Turner & Townsend has seen and resolved the asset related issues to help these businesses achieve their goals. We provide specialist sector support at every stage of a project lifecycle, from strategic business and project delivery objectives to meeting the specific challenges of the pharmaceuticals industry.

“Turner & Townsend has supported the Wellcome Trust on several major projects. They continue to demonstrate their energy and willingness to support us at all times with accurate and reliable information. They are enthusiastic team members and well respected by the diverse professional team. I would not hesitate to commission them again."

The Wellcome Trust